- ISIN
- US1101221083
- CUSIP
- 110122108
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Jan 1, 1972
Highlights
- Market Cap
- $111.78B
- Enterprise Value
- $148.97B
- EPS (TTM)
- $3.57
- PE Ratio
- 15.34
- PEG Ratio
- 0.88
- Total Revenue (TTM)
- $48.48B
- Gross Profit (TTM)
- $33.33B
- EBITDA (TTM)
- $13.34B
- Year Range
- $42.52 - $62.89
- Target Price
- $62.00
- ROA (TTM)
- 8.41%
- ROE (TTM)
- 36.25%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BMY Performance Chart
Bristol-Myers Squibb Company (BMY) is up 3.7% since the beginning of the year. At $55 per share, BMY is trading 13.0% below its 52-week high of $63. Investors who bought $1,000 worth of BMY shares 5 years ago would now be looking at an investment worth $1,025.
Loading charts...
Returns By Period
Bristol-Myers Squibb Company (BMY) has returned 3.67% so far this year and 22.56% over the past 12 months. Over the last ten years, BMY has returned 0.91% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Bristol-Myers Squibb Company
- 1D
- 1.30%
- 1M
- -8.01%
- YTD
- 3.67%
- 6M
- 2.30%
- 1Y
- 22.56%
- 3Y*
- -1.14%
- 5Y*
- 0.49%
- 10Y*
- 0.91%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BMY Monthly Returns History
Based on dividend-adjusted daily data since Jun 1, 1972, BMY's average daily return is +0.05%, while the average monthly return is +0.96%. At this rate, an investment would double in approximately 6.0 years.
Historically, 56% of months were positive and 44% were negative. The best month was Oct 1974 with a return of +42.1%, while the worst month was Apr 2002 at -28.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 8 months.
On a daily basis, BMY closed higher 48% of trading days. The best single day was Oct 21, 1987 with a return of +15.9%, while the worst single day was Apr 19, 2000 at -22.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.26% | 13.30% | -2.76% | 0.93% | -5.63% | -4.34% | 3.67% | ||||||
| 2025 | 5.38% | 1.14% | 2.30% | -16.80% | -3.82% | -4.12% | -5.20% | 8.94% | -4.41% | 3.55% | 6.79% | 9.63% | 0.11% |
| 2024 | -3.65% | 3.85% | 6.86% | -18.03% | -6.49% | 1.07% | 16.26% | 5.03% | 3.58% | 9.00% | 6.19% | -4.49% | 15.81% |
| 2023 | 1.77% | -5.08% | 0.51% | -2.87% | -3.49% | -0.76% | -1.89% | -0.87% | -5.86% | -10.32% | -4.17% | 3.91% | -26.14% |
| 2022 | 4.99% | 5.83% | 7.13% | 3.07% | 0.24% | 2.76% | -4.18% | -8.63% | 5.46% | 9.80% | 3.63% | -10.38% | 18.98% |
| 2021 | -0.97% | -0.16% | 3.74% | -1.12% | 5.29% | 1.67% | 2.32% | -1.49% | -10.78% | -1.30% | -8.17% | 16.26% | 2.88% |
Benchmark Metrics
Bristol-Myers Squibb Company has an annualized alpha of 4.96%, beta of 0.79, and R2 of 0.27 versus S&P 500 Index. Calculated based on daily prices since June 01, 1972.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (85.51%) than losses (80.44%) - typical of diversified or defensive assets.
- R2 of 0.27 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.96%
- Beta
- 0.79
- R²
- 0.27
- Upside Capture
- 85.51%
- Downside Capture
- 80.44%
Return for Risk
Risk / Return Rank
BMY ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BMY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.19 | ||
| Sortino ratioReturn per unit of downside risk | -1.35 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.37 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 1.81 | 2.78 | -0.98 |
| Martin ratioReturn relative to average drawdown | 4.13 | 12.44 | -8.31 |
Dividends
Dividend History
Bristol-Myers Squibb Company provided a 4.57% dividend yield over the last twelve months, with an annual payout of $2.50 per share. The company has been increasing its dividends for 4 consecutive years.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $2.50 | $2.48 | $2.40 | $2.28 | $2.16 | $1.47 | $2.29 | $1.64 | $1.60 | $1.56 | $1.14 | $1.49 |
Dividend yield | 4.57% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Monthly Dividends
The table displays the monthly dividend distributions for Bristol-Myers Squibb Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.63 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $1.26 | ||||||
| 2025 | $0.62 | $0.00 | $0.00 | $0.62 | $0.00 | $0.00 | $0.62 | $0.00 | $0.00 | $0.62 | $0.00 | $0.00 | $2.48 |
| 2024 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $2.40 |
| 2023 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $2.28 |
| 2022 | $0.54 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $2.16 |
| 2021 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.00 | $0.49 | $0.00 | $0.49 | $0.00 | $0.00 | $0.00 | $1.47 |
Dividend Yield & Payout
Dividend Yield
Bristol-Myers Squibb Company has a dividend yield of 4.57%, which is quite average when compared to the overall market.
Payout Ratio
Bristol-Myers Squibb Company has a payout ratio of 69.69%, which is quite average when compared to the overall market. This suggests that Bristol-Myers Squibb Company strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bristol-Myers Squibb Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bristol-Myers Squibb Company was 72.03%, occurring on Jul 24, 2002. Recovery took 2726 trading sessions.
The current Bristol-Myers Squibb Company drawdown is 21.28%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -72.03%Jul 2002 | 2y 8mo | 10y 10mo | 13y 6moOct 1999 - May 2013 |
1974 bear market1974 | -56.31%Oct 1974 | 2y 1mo | 1y 1mo | 3y 3moAug 1972 - Nov 1975 |
2024 bear market2024 | -47.67%Jul 2024 | 1y 7mo | — | 3y 6moDec 2022 - now |
2019 bear market2019 | -39.30%Jul 2019 | 3y 7d | 1y 10mo | 4y 10moJul 2016 - May 2021 |
1993 bear market1993 | -38.47%Aug 1993 | 1y 7mo | 2y 1mo | 3y 8moJan 1992 - Oct 1995 |
Drawdown Indicators
| BMY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -56.78% | -15.25% |
Max Drawdown (1Y)Largest decline over 1 year | -12.53% | -9.10% | -3.43% |
Max Drawdown (3Y)Largest decline over 3 years | -36.02% | -18.90% | -17.12% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -25.43% | -22.24% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -33.92% | -13.75% |
Current DrawdownCurrent decline from peak | -21.28% | -1.80% | -19.48% |
Average DrawdownAverage peak-to-trough decline | -22.38% | -10.71% | -11.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.48% | 2.03% | +3.45% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bristol-Myers Squibb Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bristol-Myers Squibb Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BMY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/E ratio of 15.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BMY compared to other companies in the Drug Manufacturers - General industry. BMY currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BMY relative to other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BMY in comparison with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/B value of 5.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BMY
Add Bristol-Myers Squibb Company to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BMY